Tumor-associated macrophages secrete CCL2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
Breast cancer is the most prevalent malignancy among women. Although endocrine therapy is effective, development of endocrine resistance is a major clinical challenge. The tumor microenvironment (TME) promotes tumor malignancy, and tumor-associated macrophages (TAMs) within the TME play a crucial role in endocrine resistance. Here, we aimed to elucidate the relationship between TAMs and the endocrine-resistant phenotype of breast cancer. Macrophages were cultured with conditioned medium (CM) from tamoxifen-sensitive (MCF7-S) or -resistant (MCF7-R) MCF7 breast cancer cells. M2 polarization was detected by CD163 immunofluorescence. To determine the effect on endocrine resistance, MCF7 cells were cultured in the supernatant of different TAMs, and then treated with tamoxifen. CCL2 immunohistochemistry was performed on pathological sections from 100 patients with invasive estrogen receptor-positive breast cancer. We found that macrophages cultured in the CM of MCF7-S and MCF7-R cells were induced into TAMs, with a more obvious M2 polarization in the latter. Tamoxifen resistance was increased by culture in TAM medium. TAMs secreted CCL2, which increased endocrine resistance in breast cancer cells via activation of the PI3K/Akt/mTOR signaling pathway. High expression of CCL2 was correlated with the infiltration of CD163+ macrophages (r = 0.548, P < 0.001), and patients with high CCL2 expression presented shorter progression-free survival than those with low CCL2 expression (P < 0.05). We conclude that CCL2 secreted by TAMs activates PI3K/Akt/mTOR signaling and promotes an endocrine resistance feedback loop in the TME, suggesting that CCL2 and TAMs may be novel therapeutic targets for patients with endocrine-resistant breast cancer.